| Literature DB >> 30622836 |
Pedro Manzke1,2, Talyta Grippe1,2, Georgia L Tavares1, Lucas C Leal1, Emmanuel Roze3,4, Emmanuelle Apartis3,5, Ronaldo Maciel Dias1, André G F Ferreira1.
Abstract
Background: The clinical spectrum of anti-glutamic acid decarboxylase (GAD) antibody-associated neurologic syndromes is expanding, with focal, generalized, and atypical forms. Case Report: We describe a 59-year-old female showing continuous right lower limb myoclonus and mild encephalopathy. These symptoms started 2 weeks prior to evaluation. The patient had great improvement with intravenous steroids. An autoantibody panel was positive for anti-GAD. Discussion: Various clinical manifestations, including myoclonus, may relate to anti-GAD antibodies. The treatment options available include symptomatic drugs, intravenous immunoglobulin, steroids, and other immunosuppressant agents.Entities:
Keywords: Anti-glutamic acid decarboxylase antibodies; autoimmunity; epilepsy; myoclonus; stiff person syndrome
Mesh:
Substances:
Year: 2018 PMID: 30622836 PMCID: PMC6315060 DOI: 10.7916/D8NK4XVP
Source DB: PubMed Journal: Tremor Other Hyperkinet Mov (N Y) ISSN: 2160-8288
Video 1.Segment 1. Before Treatment. Spontaneous, continuous, irregular, brief, involuntary movements restricted to the right lower limb, suggestive of myoclonic jerks, that worsen in amplitude and frequency with action. There is no rigidity or stimulus sensitivity. Gait is impaired by the involuntary movements. Segment 2. After Treatment – 1-Month Follow-up. Intravenous methylprednisolone pulse therapy improved symptoms. Involuntary movements are no longer observed. Gait is markedly improved.